Home Angiogenesis FGFR inhibitor - c-RET inhibitor - CSF-1R inhibitor - PDGFR inhibitor - VEGFR inhibitor - Apoptosis related activator - c-Kit inhibitor Erdafitinib For research use only.

Erdafitinib

Synonyms: JNJ-42756493

Erdafitinib is a potent and selective orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Erdafitinib also binds to RET (c-RET), CSF-1R, PDGFR-α/PDGFR-β, FLT4, Kit (c-Kit) and VEGFR-2 and induces cellular apoptosis.

Erdafitinib Chemical Structure

Erdafitinib Chemical Structure

CAS No. 1346242-81-6

Purity & Quality Control

Erdafitinib Related Products

Signaling Pathway

FGFR Signaling Pathways

FGFR Signaling Pathway

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BA/F3 Function assay 24 hrs Inhibition of FGFR3 (unknown origin) transfected in mouse BA/F3 cells assessed as decrease in cell proliferation in absence of mouse IL3 after 24 hrs by Alamar blue assay, IC50 = 0.01585 μM. ChEMBL
BA/F3 Function assay 24 hrs Inhibition of FGFR1 (unknown origin) transfected in mouse BA/F3 cells assessed as decrease in cell proliferation in absence of mouse IL3 after 24 hrs by Alamar blue assay, IC50 = 0.08318 μM. ChEMBL
BA/F3 Function assay 24 hrs Inhibition of VEGFR2 (unknown origin) transfected in mouse BA/F3 cells assessed as decrease in cell proliferation in absence of mouse IL3 after 24 hrs by Alamar blue assay, IC50 = 3.31131 μM. ChEMBL
Click to View More Cell Line Experimental Data

Biological Activity

Description Erdafitinib is a potent and selective orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Erdafitinib also binds to RET (c-RET), CSF-1R, PDGFR-α/PDGFR-β, FLT4, Kit (c-Kit) and VEGFR-2 and induces cellular apoptosis.
Targets
FGFR [1] RET [3] CSF-1R [3] PDGFR [3] Kit [3] Click to View More Targets
In vitro
In vitro

JNJ-42756493 is a potent, oral pan-FGFR tyrosine kinase inhibitor with half-maximal inhibitory concentration values in the low nanomolar range for all members of the FGFR family (FGFR1 to FGFR4), with minimal activity on vascular endothelial growth factor receptor (VEGFR) kinases compared with FGFR kinases (approximately 20-fold potency difference). In vitro, the proliferation of cells treated with JNJ-42756493 is decreased, associated with increased apoptotic death and decreased cell survival[2].
Cell Research Cell lines HCT116, HCA7, Caco2 and NCI-H716 cells
Concentrations --
Incubation Time 72 h
Method

The effect of varying drug concentrations on cell growth and survival is evaluated at 72 h using sulforhodamine B (SRB) assay for the adherent cells (HCT116, HCA7, Caco2) and trypan blue dye exclusion for the suspension cells, NCI-H716.
Experimental Result Images Methods Biomarkers Images PMID
Western blot FGFR2 / p-FGFR PARP / Cleaved PARP / AKT / p-AKT / p-ERK / ERK2 26675289
Growth inhibition assay Cell viability 26675289
In Vivo
In vivo

In vivo, growth of NCI-H716 tumors is delayed by 5 days by drug treatment alone, although when drug delivery is stopped the relative tumor volume increased compared to control[2]. JNJ-42756493 shows favorable drug like properties and displays a high distribution to lung, liver and kidney tissue. JNJ-42756493 is well tolerated at efficacious doses and results in potent dose-dependent antitumor activity accompanied by pharmacodynamic modulation of tumor FGFR and downstream pathway components[1].
Animal Research Animal Models NMRI nu/nu female mice
Dosages 40 mg/kg
Administration by gavage
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05567185 Recruiting
Urinary Bladder Neoplasms|Receptors Fibroblast Growth Factor
Janssen Pharmaceutical K.K.
 March 3 2023 Phase 1
NCT05316155 Recruiting
Urinary Bladder Neoplasms|Receptors Fibroblast Growth Factor
Janssen Research & Development LLC
 April 11 2022 Phase 1
NCT05052372 Terminated
Bladder Cancer|Urothelial Carcinoma|Transitional Cell Carcinoma|Platinum-Resistant Urothelial Carcinoma|Bladder Urothelial Carcinoma|FGFR Mutation|FGFR2 Gene Mutation|FGFR3 Gene Mutation|FGFR2 Amplification|Locally Advanced Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Refractory Bladder Carcinoma|Refractory Bladder Urothelial Carcinoma
xCures
 November 21 2021 --
NCT04330248 Completed
Healthy
Johnson & Johnson Pharmaceutical Research & Development L.L.C.
 March 31 2020 Phase 1
NCT04083976 Active not recruiting
Advanced Solid Tumor
Janssen Research & Development LLC
 November 20 2019 Phase 2

Chemical Information & Solubility

Molecular Weight 446.54 Formula

C25H30N6O2
CAS No. 1346242-81-6 SDF Download Erdafitinib SDF
Smiles CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 89 mg/mL ( (199.31 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 89 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Erdafitinib | Erdafitinib supplier | purchase Erdafitinib | Erdafitinib cost | Erdafitinib manufacturer | order Erdafitinib | Erdafitinib distributor